Search
Results: 6691
Best practice in Active Surveillance for men with prostate cancer
Samuel WD Merriel, Liz Hetherington, Andrew Seggie, Joanna T Castle, William Cross, Monique J Roobol, Vincent Gnanapragasam, Caroline M Moore, Prostate Cancer UK Expert Reference Group on Active Surveillance
Apr 04, 2019
OBJECTIVES: To develop a consensus statement on current best practice of active surveillance (AS) in the UK, informed by patients and clinical experts. SUBJECTS AND METHODS: A consensus statement was drafted on the basis of...
The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates.
Claudia Buhigas, Anne Y Warren, Wing-Kit Leung, Hayley C Whitaker, Hayley J Luxton, Steve Hawkins, Jonathan Kay, Adam Butler, Yaobo Xu, Dan J Woodcock, Sue Merson, Fiona M Frame, Atef Sahli, Federico Abascal, CRUK-ICGC Prostate Cancer Group, Iñigo Martincorena, G Steven Bova, Christopher S Foster, Peter Campbell, Norman J Maitland, David E Neal, Charlie E Massie, Andy G Lynch, Rosalind A Eeles, Colin S Cooper, David C Wedge, Daniel S Brewer
Sep 22, 2022
BACKGROUND: Up to 80% of cases of prostate cancer present with multifocal independent tumour lesions leading to the concept of a field effect present in the normal prostate predisposing to cancer development. In the present...
Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer
Abstract: Background: PREDICT Prostate is an endorsed prognostic model that provides individualised long-term prostate cancer-specific and overall survival estimates. The model, derived from UK data, estimates potential...
Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer
Abstract: Background: PREDICT Prostate is an endorsed prognostic model that provides individualised long-term prostate cancer-specific and overall survival estimates. The model, derived from UK data, estimates potential...
Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer
Abstract: Background: PREDICT Prostate is an endorsed prognostic model that provides individualised long-term prostate cancer-specific and overall survival estimates. The model, derived from UK data, estimates potential...
The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates.
Claudia Buhigas, Anne Y Warren, Wing-Kit Leung, Hayley C Whitaker, Hayley J Luxton, Steve Hawkins, Jonathan Kay, Adam Butler, Yaobo Xu, Dan J Woodcock, Sue Merson, Fiona M Frame, Atef Sahli, Federico Abascal, CRUK-ICGC Prostate Cancer Group, Iñigo Martincorena, G Steven Bova, Christopher S Foster, Peter Campbell, Norman J Maitland, David E Neal, Charlie E Massie, Andy G Lynch, Rosalind A Eeles, Colin S Cooper, David C Wedge, Daniel S Brewer
Oct 24, 2022
BACKGROUND: Up to 80% of cases of prostate cancer present with multifocal independent tumour lesions leading to the concept of a field effect present in the normal prostate predisposing to cancer development. In the present...
HES5 silencing is an early and recurrent change in prostate tumourigenesis.
Charles E Massie, Inmaculada Spiteri, Helen Ross-Adams, Hayley Luxton, Jonathan Kay, Hayley C Whitaker, Mark J Dunning, Alastair D Lamb, Antonio Ramos-Montoya, Daniel S Brewer, Colin S Cooper, Rosalind Eeles, UK Prostate ICGC Group, Anne Y Warren, Simon Tavaré, David E Neal, Andy G Lynch
Mar 12, 2015
AR ERG HES5 HES6 Notch epigenetics Methylation prostate cancer Basic Helix-Loop-Helix Transcription Factors Carcinogenesis Cell Line Tumor DNA Methylation Epigenesis Genetic Gene Expression Profiling Gene Expression Regulation Neoplastic Humans Male Promoter Regions Genetic Prostatic Neoplasms Repressor Proteins Trans-Activators Transcriptional Regulator ERG
Understanding of prognosis in non-metastatic prostate cancer
PREDICT Prostate is an individualised prognostic model that provides long-term survival estimates for men diagnosed with non-metastatic prostate cancer ( www.prostate.predict.nhs.uk ). In this study clinician estimates of...
Risk stratification for prostate cancer management
M. G. Parry, T. E. Cowling, A. Sujenthiran, J. Nossiter, B. Berry, P. Cathcart, A. Aggarwal, H. Payne, J. van der Meulen, N. W. Clarke, V. J. Gnanapragasam
Jun 06, 2020
Abstract: Background: The five-tiered Cambridge Prognostic Group (CPG) classification is a better predictor of prostate cancer-specific mortality than the traditional three-tiered classification (low, intermediate, and high...
Risk stratification for prostate cancer management
M. G. Parry, T. E. Cowling, A. Sujenthiran, J. Nossiter, B. Berry, P. Cathcart, A. Aggarwal, H. Payne, J. van der Meulen, N. W. Clarke, V. J. Gnanapragasam
May 28, 2021
Abstract: Background: The five-tiered Cambridge Prognostic Group (CPG) classification is a better predictor of prostate cancer-specific mortality than the traditional three-tiered classification (low, intermediate, and high...
Understanding of prognosis in non-metastatic prostate cancer
Abstract: PREDICT Prostate is an individualised prognostic model that provides long-term survival estimates for men diagnosed with non-metastatic prostate cancer (www.prostate.predict.nhs.uk). In this study clinician estimates...
Homeobox B13 G84E Mutation and Prostate Cancer Risk.
Tommy Nyberg, Koveela Govindasami, Goska Leslie, Tokhir Dadaev, Elizabeth Bancroft, Holly Ni Raghallaigh, Mark N Brook, Nafisa Hussain, Diana Keating, Andrew Lee, Romayne McMahon, Angela Morgan, Andrea Mullen, Andrea Osborne, Reshma Rageevakumar, UK Genetic Prostate Cancer Study Collaborators, Zsofia Kote-Jarai, Rosalind Eeles, Antonis C Antoniou
Dec 19, 2018
BACKGROUND: The homeobox B13 (HOXB13) G84E mutation has been recommended for use in genetic counselling for prostate cancer (PCa), but the magnitude of PCa risk conferred by this mutation is uncertain. OBJECTIVE: To obtain...
A core outcome set for localised prostate cancer effectiveness trials
S MacLennan, PR Williamson, H Bekema, M Campbell, C Ramsay, J N'Dow, S MacLennan, L Vale, P Dahm, N Mottet, T Lam, G Stewart, COMPACTERS Study Group
Jun 26, 2017
$\textbf{OBJECTIVE}$: To develop a core outcome set (COS) applicable for effectiveness trials of all interventions for localised prostate cancer. Many treatments exist for localised prostate cancer, although it is unclear which...
Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.
Colin S Cooper, Rosalind Eeles, David C Wedge, Peter Van Loo, Gunes Gundem, Ludmil B Alexandrov, Barbara Kremeyer, Adam Butler, Andrew G Lynch, Niedzica Camacho, Charlie E Massie, Jonathan Kay, Hayley J Luxton, Sandra Edwards, Zsofia Kote-Jarai, Nening Dennis, Sue Merson, Daniel Leongamornlert, Jorge Zamora, Cathy Corbishley, Sarah Thomas, Serena Nik-Zainal, Sarah O'Meara, Lucy Matthews, Jeremy Clark, Rachel Hurst, Richard Mithen, Robert G Bristow, Paul C Boutros, Michael Fraser, Susanna Cooke, Keiran Raine, David Jones, Andrew Menzies, Lucy Stebbings, Jon Hinton, Jon Teague, Stuart McLaren, Laura Mudie, Claire Hardy, Elizabeth Anderson, Olivia Joseph, Victoria Goody, Ben Robinson, Mark Maddison, Stephen Gamble, Christopher Greenman, Dan Berney, Steven Hazell, Naomi Livni, ICGC Prostate Group, Cyril Fisher, Christopher Ogden, Pardeep Kumar, Alan Thompson, Christopher Woodhouse, David Nicol, Erik Mayer, Tim Dudderidge, Nimish C Shah, Vincent Gnanapragasam, Thierry Voet, Peter Campbell, Andrew Futreal, Douglas Easton, Anne Y Warren, Christopher S Foster, Michael R Stratton, Hayley C Whitaker, Ultan McDermott, Daniel S Brewer, David E Neal
Nov 01, 2018
Genome-wide DNA sequencing was used to decrypt the phylogeny of multiple samples from distinct areas of cancer and morphologically normal tissue taken from the prostates of three men. Mutations were present at high levels in...
Height, selected genetic markers and prostate cancer risk
Artitaya Lophatananon, Sarah Stewart-Brown, Zsofia Kote-Jarai, Ali Amin Al Olama, Sara Benlloch Garcia, David E Neal, Freddie C Hamdy, Jenny L Donovan, Graham G Giles, Liesel M Fitzgerald, Melissa C Southey, Paul Pharoah, Nora Pashayan, Henrik Gronberg, Fredrik Wiklund, Markus Aly, Janet L Stanford, Hermann Brenner, Aida K Dieffenbach, Volker Arndt, Jong Y Park, Hui-Yi Lin, Thomas Sellers, Chavdar Slavov, Radka Kaneva, Vanio Mitev, Jyotsna Batra, Amanda Spurdle, Judith A Clements, APCB BioResource, PRACTICAL Consortium, Douglas Easton, Rosalind A Eeles, Kenneth Muir
Dec 08, 2017
BACKGROUND: Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer. METHODS: We analysed data...
The evolutionary history of lethal metastatic prostate cancer
G Gundem, P Van Loo, B Kremeyer, LB Alexandrov, JMC Tubio, E Papaemmanuil, DS Brewer, HML Kallio, G Högnäs, M Annala, K Kivinummi, V Goody, C Latimer, S O'Meara, KJ Dawson, W Isaacs, MR Emmert-Buck, M Nykter, C Foster, Z Kote-Jarai, D Easton, HC Whitaker, ICGC Prostate Group, DE Neal, CS Cooper, RA Eeles, T Visakorpi, PJ Campbell, U McDermott, DC Wedge, GS Bova
Sep 12, 2017
Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.
S Sanghera, S Mohiuddin, J Coast, K Garfield, S Noble, C Metcalfe, JA Lane, EL Turner, D Neal, FC Hamdy, RM Martin, JL Donovan, ProtecT study group
Nov 26, 2020
BACKGROUND: Optimal management strategies for clinically localised prostate cancer are debated. Using median 10-year data from the largest randomised controlled trial to date (ProtecT), the lifetime cost-effectiveness of three...
Germline variation at 8q24 and prostate cancer risk in men of European ancestry.
Marco Matejcic, Edward J Saunders, Tokhir Dadaev, Mark N Brook, Kan Wang, Xin Sheng, Ali Amin Al Olama, Fredrick R Schumacher, Sue A Ingles, Koveela Govindasami, Sara Benlloch, Sonja I Berndt, Demetrius Albanes, Stella Koutros, Kenneth Muir, Victoria L Stevens, Susan M Gapstur, Catherine M Tangen, Jyotsna Batra, Judith Clements, Henrik Gronberg, Nora Pashayan, Johanna Schleutker, Alicja Wolk, Catharine West, Lorelei Mucci, Peter Kraft, Géraldine Cancel-Tassin, Karina D Sorensen, Lovise Mæhle, Eli M Grindedal, Sara S Strom, David E Neal, Freddie C Hamdy, Jenny L Donovan, Ruth C Travis, Robert J Hamilton, Barry Rosenstein, Yong-Jie Lu, Graham G Giles, Adam S Kibel, Ana Vega, Jeanette T Bensen, Manolis Kogevinas, Kathryn L Penney, Jong Y Park, Janet L Stanford, Cezary Cybulski, Børge G Nordestgaard, Hermann Brenner, Christiane Maier, Jeri Kim, Manuel R Teixeira, Susan L Neuhausen, Kim De Ruyck, Azad Razack, Lisa F Newcomb, Davor Lessel, Radka Kaneva, Nawaid Usmani, Frank Claessens, Paul A Townsend, Manuela Gago-Dominguez, Monique J Roobol, Florence Menegaux, Kay-Tee Khaw, Lisa A Cannon-Albright, Hardev Pandha, Stephen N Thibodeau, Daniel J Schaid, PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Fredrik Wiklund, Stephen J Chanock, Douglas F Easton, Rosalind A Eeles, Zsofia Kote-Jarai, David V Conti, Christopher A Haiman
Dec 18, 2018
Chromosome 8q24 is a susceptibility locus for multiple cancers, including prostate cancer. Here we combine genetic data across the 8q24 susceptibility region from 71,535 prostate cancer cases and 52,935 controls of European...
Identification of stromally expressed molecules in the prostate by tag-profiling of cancer-associated fibroblasts, normal fibroblasts and fetal prostate.
The stromal microenvironment has key roles in prostate development and cancer, and cancer-associated fibroblasts (CAFs) stimulate tumourigenesis via several mechanisms including the expression of pro-tumourigenic factors....
The Max-Min Group Contest
We investigate a group all-pay auction in which each group's effort is represented by the minimum among the effort levels exerted by the group members and the prize is a group-specific public good. We fully characterize the...
The Max-Min Group Contest
We investigate a group all-pay auction in which each group's effort is represented by the minimum among the effort levels exerted by the group members and the prize is a group-specific public good. We fully characterize the...
Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen
Sean Harrison, Kate Tilling, Emma L. Turner, Richard M. Martin, Rosie Lennon, J. Athene Lane, Jenny L. Donovan, Freddie C. Hamdy, David E. Neal, J. L. H. Ruud Bosch, Hayley E. Jones
Jun 06, 2020
Abstract: Purpose: The relationship between body mass index (BMI) and prostate cancer remains unclear. However, there is an inverse association between BMI and prostate-specific antigen (PSA), used for prostate cancer screening....
Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen.
Sean Harrison, Kate Tilling, Emma L Turner, Richard M Martin, Rosie Lennon, J Athene Lane, Jenny L Donovan, Freddie C Hamdy, David E Neal, JLH Ruud Bosch, Hayley E Jones
Mar 11, 2021
PURPOSE: The relationship between body mass index (BMI) and prostate cancer remains unclear. However, there is an inverse association between BMI and prostate-specific antigen (PSA), used for prostate cancer screening. We...
Supporting prostate cancer survivors in primary care
Eila K Watson, Bethany Shinkins, Lauren Matheson, Richeal M Burns, Emma Frith, David Neal, Freddie Hamdy, Fiona M Walter, David Weller, Claire Wilkinson, Sara Faithfull, Prasanna Sooriakumaran, Christof Kastner, Christine Campbell, Richard D Neal, Hugh Butcher, Mike Matthews, Rafael Perera, Jane Wolstenholme, Peter W Rose
Mar 01, 2018
PURPOSE: This study sought to test the acceptability and feasibility of a nurse-led psycho-educational intervention (NLPI) delivered in primary care to prostate cancer survivors, and to provide preliminary estimates of the...
Feasibility Nurse-led intervention Pilot trial PRIMARY CARE prostate cancer randomised controlled trial self-efficacy Aged Cancer Survivors England Female Humans Male Middle Aged Nurse's Role Nurse-Patient Relations Patient Education as Topic Pilot Projects Primary Health Care Prostatic Neoplasms Quality of life Surveys and Questionnaires
The genomic evolution of human prostate cancer.
Prostate cancers are highly prevalent in the developed world, with inheritable risk contributing appreciably to tumour development. Genomic heterogeneity within individual prostate glands and between patients derives...
|
|< |
< |
1 |